help button home button Endocrine Society Molecular Endocrinology ENDO 08 Sessions Library
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Molecular Endocrinology, doi:10.1210/me.2007-0025
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow NURSA Molecule Pages Link
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marzolini, C.
Right arrow Articles by Kim, R. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marzolini, C.
Right arrow Articles by Kim, R. B.
Molecular Endocrinology 21 (8): 1769-1780
Copyright © 2007 by The Endocrine Society

A Common Polymorphism in the Bile Acid Receptor Farnesoid X Receptor Is Associated with Decreased Hepatic Target Gene Expression

Catia Marzolini, Rommel G. Tirona, Guillermo Gervasini, Balasubramanian Poonkuzhali, Mahfoud Assem, Wooin Lee, Brenda F. Leake, John D. Schuetz, Erin G. Schuetz and Richard B. Kim

Division of Clinical Pharmacology, Department of Medicine (C.M., B.F.L.) and Division of Hematology/Oncology, Department of Medicine (W.L.), Vanderbilt University Medical Center, Nashville, Tennessee 37232; Division of Clinical Pharmacology, Department of Medicine (R.G.T., R.B.K.) and Department of Physiology and Pharmacology (R.G.T., R.B.K.), The University of Western Ontario, London, Ontario, Canada N6A 5A5; Department of Pharmacology and Psychiatry (G.G.), Medical School, University of Extremadura, 06071 Badajoz, Spain; and Department of Pharmaceutical Sciences (B.P., M.A., J.D.S., E.G.S.), St. Jude Children’s Research Hospital, Memphis, Tennessee 38105

Address all correspondence and requests for reprints to: Dr. Richard B. Kim, Division of Clinical Pharmacology, Department of Medicine, The University of Western Ontario, 339 Windermere Road, Room ALL-152, London Health Sciences Centre, University Hospital, London, Ontario, Canada N6A 5A5. E-mail: richard.kim{at}lhsc.on.ca.

The farnesoid X receptor (FXR or NR1H4) is an important bile-acid-activated, transcriptional regulator of genes involved in bile acid, lipid, and glucose homeostasis. Accordingly, interindividual variations in FXR expression and function could manifest as variable susceptibility to conditions such as cholesterol gallstone disease, atherosclerosis, and diabetes. We performed an FXR polymorphism discovery analysis of European-, African-, Chinese-, and Hispanic-Americans and identified two rare gain-of-function variants and a common single nucleotide polymorphism resulting in a G-1T substitution in the nucleotide adjacent to the translation initiation site (FXR*1B) with population allelic frequencies ranging from 2.5 to 12%. In cell-based transactivation assays, FXR*1B (-1T) activity was reduced compared with FXR*1A (-1G). This reduced activity for FXR*1B resulted from neither decreased translational efficiency nor the potential formation of a truncated translational variant. To further define the relevance of this polymorphism, gene expression was examined in a human liver bank to reveal that levels of the FXR target genes small heterodimer partner and organic anion transporting polypeptide 1B3 were significantly reduced in livers harboring an FXR*1B allele. These findings are the first to identify the presence of a common genetic variant in FXR with functional consequences that could contribute to disease risk or therapeutic outcomes.

NURSA Molecule Pages Link:

Nuclear Receptors:   SHP  |  FXRα



This article has been cited by other articles:


Home page
Physiol. Rev.Home page
P. Lefebvre, B. Cariou, F. Lien, F. Kuipers, and B. Staels
Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation
Physiol Rev, January 1, 2009; 89(1): 147 - 191.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
B. Kong, J. P. Luyendyk, O. Tawfik, and G. L. Guo
Farnesoid X Receptor Deficiency Induces Nonalcoholic Steatohepatitis in Low-Density Lipoprotein Receptor-Knockout Mice Fed a High-Fat Diet
J. Pharmacol. Exp. Ther., January 1, 2009; 328(1): 116 - 122.
[Abstract] [Full Text] [PDF]


Home page
PhysiologyHome page
J. J. Eloranta and G. A. Kullak-Ublick
The Role of FXR in Disorders of Bile Acid Homeostasis
Physiology, October 1, 2008; 23(5): 286 - 295.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
C. Healan-Greenberg, J. F. Waring, D. J. Kempf, E. A. G. Blomme, R. G. Tirona, and R. B. Kim
A Human Immunodeficiency Virus Protease Inhibitor Is a Novel Functional Inhibitor of Human Pregnane X Receptor
Drug Metab. Dispos., March 1, 2008; 36(3): 500 - 507.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society